Insights from Egyptian ticagrelor study in patients who presented with acute coronary syndrome (ETS in ACS)
Abstract Background Dual antiplatelet therapy with aspirin and a thienopyridine is used to prevent thrombotic complications of acute coronary syndrome (ACS) and percutaneous coronary interventions (PCI). Ticagrelor is an oral, reversible inhibitor of the adenosine diphosphate receptor P2Y12 with a f...
Main Authors: | Hesham S. Taha, Hossam Kandil, Nabil Farag, Amr Zaki, Hossam Mahrous, Mirna M. Shaker |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2022-06-01
|
Series: | The Egyptian Heart Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43044-022-00290-w |
Similar Items
-
Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice
by: Liam Mullen, et al.
Published: (2021-04-01) -
Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01) -
Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
by: Chen Ning, et al.
Published: (2024-03-01) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)